title: Comment re: continuous rather than intermittent administration of fenretinide in leukoplakia.
authors.forename: Franca
authors.initials: F
authors.lastname: Formelli
authors.forename: Elena
authors.initials: E
authors.lastname: Cavadini
authors.forename: Valentina
authors.initials: V
authors.lastname: Appierto
authors.forename: Paolo
authors.initials: P
authors.lastname: Tiberio
authors.forename: Roberto
authors.initials: R
authors.lastname: Grigolato
authors.forename: Fausto
authors.initials: F
authors.lastname: Chiesa
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Tradati
authors.forename: Stefano
authors.initials: S
authors.lastname: Persiani
mesh_terms: D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D017313:Fenretinide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007972:Leukoplakia, Oral / Q000188:drug therapy*; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D017313:Fenretinide